Neoplastic Process – Page 36

Novartis’ Scemblix Demonstrates Superior Efficacy and Safety in Newly Diagnosed Leukemia Patients ###

11 months ago talkbio0Tagged Clinical Oncology ( ASCO, Gleevec, leukemia, Myeloid Leukemia, Chronic, Novartis, Scemblix, Tyrosine Kinase Inhibitors [MoA]

Novartis, Scemblix, Leukemia, Chronic Myeloid Leukemia (CML), Tyrosine Kinase Inhibitors (TKIs), Gleevec, American Society of Clinical Oncology (ASCO)

Early Detection and Personalized Treatment of Colorectal Cancer: The Promise of Whole Genome Sequencing-Based Circulating Tumor DNA Tracking” ###

11 months ago talkbio0Tagged Adjuvant Therapy, Circulating, Circulating Tumor DNA, Colorectal Carcinoma, Detection, Liquid Biopsy, Molecular residual disease, MRD, Personalized Treatment, Whole Genome Sequencing

Circulating tumor DNA (ctDNA), Whole genome sequencing (WGS), Colorectal cancer, Early detection, Personalized treatment, Adjuvant therapy, Molecular residual disease (MRD), Liquid biopsies

Regulatory Tracker: Lilly’s Retevmo Secures Pediatric Cancer FDA Nod ###

11 months ago talkbio0Tagged Accelerated, Approved, Eli, Eli Lilly, LIBRETTO-121 trial, Malignant Childhood Neoplasm, Malignant neoplasm of thyroid, RET-altered, Retevmo, selpercatinib, Solid Neoplasm, United States Food and Drug Administration

Retevmo, Eli Lilly, FDA approval, pediatric cancer, RET-altered, thyroid cancer, solid tumors, accelerated approval, LIBRETTO-121 trial, selpercatinib

Gilead and Cartography Collaborate to Identify Novel Antigen Targets for Cancer Therapy

11 months ago talkbio0Tagged Adenocarcinoma of lung (disorder), Antigens, Biosciences, Cancer Therapeutic Procedure, Cartography, Cervical Atlas, Drug Development, Gilead Sciences, Neoplasms, summit, targets, Technology Platform, Triple Negative Breast Neoplasms

Gilead Sciences, Cartography Biosciences, cancer therapy, antigen targets, triple-negative breast cancer, lung adenocarcinoma, ATLAS platform, SUMMIT platform, oncology, drug development.

BioNTech Strengthens ADC Partnership with China’s MediLink, Investing $25M Upfront

11 months ago talkbio0Tagged Antibody-Drug Conjugates, BioNTech, biotech, China, Collaboration, Germany, MediLink, Solid Neoplasm, Technology Platform, TMALIN

BioNTech, MediLink Therapeutics, Antibody-Drug Conjugate (ADC), Solid Tumors, TMALIN ADC Platform, Biotech Collaboration, China, Germany

AstraZeneca and Daiichi Sankyo’s TROP2 ADC Demonstrates Clinically Meaningful Survival Improvement in Phase 3 Lung Cancer Subgroup

11 months ago talkbio0Tagged AstraZeneca, Continuance of life, Daiichi, Datopotamab, Deruxtecan, Improvement, Malignant neoplasm of lung, Nonsquamous Non-Small Cell Lung Cancer, Phase 3 trial, Sankyo, TACSTD2 gene, therapeutic autologous dendritic cells

AstraZeneca, Daiichi Sankyo, TROP2 ADC, Datopotamab Deruxtecan, Lung Cancer, Phase 3 Trial, Survival Improvement, Nonsquamous Non-Small Cell Lung Cancer

J&J Adjusts Dosing Strategy for Actinium Prostate Cancer Drug Following Early Study Setbacks

11 months ago talkbio0Tagged Actinium, Cancer Therapeutic Procedure, Cessation of life, Clinical Trials, dosing, Drug Development, Flexible, J&J, Johnson & Johnson, Malignant neoplasm of prostate

J&J, Johnson & Johnson, actinium prostate cancer drug, capped dosing, flexible dosing, patient deaths, early study, clinical trial, cancer treatment, drug development.